Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Stephanie Ware Laboratory, |
RCV000714271 | SCV000787752 | pathogenic | Restrictive cardiomyopathy | 2018-04-01 | criteria provided, single submitter | research | |
Invitae | RCV000690640 | SCV000818337 | uncertain significance | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2018-08-25 | criteria provided, single submitter | clinical testing | The observation of one or more missense substitutions at this codon (p.Pro2298Leu and p.Pro2298Ser) in affected individuals suggests that this may be a clinically significant residue (PMID: 28356264, Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has been observed to segregate with restrictive cardiomyopathy in a family (Invitae). This variant is not present in population databases (ExAC no frequency). This sequence change replaces proline with leucine at codon 2298 of the FLNC protein (p.Pro2298Leu). The proline residue is highly conserved and there is a moderate physicochemical difference between proline and leucine. |